MU Stage1 Final Rule - Drug-Drug Drug-Allergy Checks

SECTION # Section 170.302(a)—Drug-Drug, Drug-Allergy, Drug-Formulary Checks

MU OBJECTIVE Implement drug-drug and drug-allergy interaction checks

MU STAGE 1 MEASURE The EP/eligible hospital/CAH has enabled this functionality for the entire EHR reporting period

CERTIFICATION CRITERION Final Rule Text: §170.302(a). (1) Notifications. Automatically and electronically generate and indicate in real-time, notifications at the point of care for drug- drug and drug-allergy contraindications based on medication list, medication allergy list, and computerized provider order entry (CPOE). (2) Adjustments. Provide certain users with the ability to adjust notifications provided for drug-drug and drug-allergy interaction checks.

STANDARDS N/A

TEST CRITERIA # §170.302 (a) http://healthcare.nist.gov/docs/170.302.a_DrugDrugDrugAllergy_v1.0.pdf

USERS	CORE / MENU	SOLUTION DEVELOPERS	STATUS
All	CORE	Oroville	In development

---

SOLUTION DESIGN / TECHNOLOGY (Add details here)

SOLUTION COMPONENTS (Add details here - Ex. KIDS patch, Delphi code, User guide, Web resources, Manual test script, etc)

DEPENDENCIES (Add details here)

COMMENTS / NOTES (Add details here)

PREVIOUS NOTES (none)

DEVELOPMENT STATUSAlthough VistA does this now, the need for other interaction checking will be coming and the ability of the purely open source VistA to do this will be leaving because the VA is implementing the use of FirstData and will not be maintaining the interactions in the National Drug File. ePrescribing that is being built by Oroville will need to pick up that function for both patients who have new prescriptions and those who don't.

ACTION ITEMS / NEXT STEPS (Add details here)

OPEN ISSUES / QUESTIONS (Add details here)